---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-25-000146"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:18:29.917614+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LivaNova Q3 revenue $357.8M (+12.5% organic); raises FY2025 EPS guidance to $3.80-$3.90

## Summary
- Third-quarter revenue $357.8M, up 12.5% reported, 11% constant-currency, and 12.5% organic vs prior year.
- GAAP diluted EPS $0.49; adjusted diluted EPS $1.11.
- Raised FY2025 guidance: revenue growth 8.5%-9.5% constant currency, EPS $3.80-$3.90, FCF $160M-$180M.
- Initiated commercial launch of Essenz Perfusion System in China, the second-largest heart-lung machine market.
- Appointed Donald Zurbay to the Board of Directors and Audit and Compliance Committee.

## SEC filing metadata
- accession: 0001639691-25-000146
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969125000146/0001639691-25-000146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969125000146/livn-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-25-000146
- JSON: https://secwatch.observer/filing/0001639691-25-000146.json
- Plain text: https://secwatch.observer/filing/0001639691-25-000146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.